Abstracts tagged "Infection"

Abstract Number: 0585 • ACR Convergence 2025
Fungal Infections, Including Candida, in Patients With Active Axial Spondyloarthritis Treated With Secukinumab: A Pooled Analysis of 10 Phase 3 Trials
Shikha Singla¹, Linda Grinnell-Merrick², Weibin Bao³, Artem Zharkov⁴ and Abhijeet Danve⁵, ¹Medical College of Wisconsin, Milwaukee, WI, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic disease characterized by inflammatory low back pain and is often accompanied by inflammation of the peripheral joints and…
Abstract Number: 2575 • ACR Convergence 2025
Influenza and COVID-19 Vaccination Uptake Among Women with Systemic Rheumatic Diseases in New York City Assessed Between 2022 and 2024
Yongjay Kim¹, Sandhya Kannayiram², Amaya Smole³, Lucy Masto⁴, Neha Nagpal⁵, Naiva Manuela Piatchou Donfack⁵, Deanna Jannat-Khah⁵, Lisa Mandl⁵, Caroline Siegel⁵, Sarah Lieber⁵, Michael Lockshin⁵, Lisa Sammaritano⁵ and Medha Barbhaiya⁵, ¹Hospital for Special Surgery, Englewood Cliffs, NJ, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, ³Hospital for Special Surgery, Brooklyn, NY, ⁴Hospital for Special Surgery, San Francisco, CA, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Women with systemic rheumatic diseases (SRDs), and particularly those on immunosuppressive medications, are at increased risk for serious infections such as influenza and COVID-19.…
Abstract Number: 1607 • ACR Convergence 2025
Antibiotic Prophylaxis during Treatment of ANCA-associated Vasculitis with Rituximab: Data from a Multicenter Cohort
Natasha Le Blanc¹, Lillian Barra², Sasha Bernatsky³, Alison Clifford⁴, Mojtaba Dabaghjamanesh⁵, Natasha Dehghan⁶, Aurore Fifi-Mah⁷, Jean-Paul Makhzoum⁸, Nataliya Milman⁹, Medha Soowamber¹⁰, Nader Khalidi¹¹, Christian Pagnoux¹⁰, Rosalie-Selene Meunier¹², Jan Willem Cohen Tervaert⁴, Elaine Yacyshyn⁴ and Arielle Mendel¹³, ¹McGill University, Montreal, Canada, ²Western University, London, ON, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Self employed, Richmond Hill, ON, Canada, ⁶University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Universite de Montreal, Montreal, Canada, ⁹the Ottawa Hospital, Ottawa, ON, Canada, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹McMaster University, Hamilton, ON, Canada, ¹²Hopital du Sacre-Coeur-de-Montreal, Montreal, QC, Canada, ¹³McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Antibiotic prophylaxis is recommended during initial treatment of ANCA-associated vasculitis (AAV). We assessed characteristics associated with prophylaxis within a Canadian multicenter AAV cohort starting…
Abstract Number: 0606 • ACR Convergence 2025
Increased Recombinant Zoster Vaccination in SLE following Public Reimbursement: Data from Two Prospective SLE Cohorts
Arielle Mendel¹, Nathalie Amiable², Yvan St-Pierre³, Sasha Bernatsky⁴, Ines Colmegna⁵, Michaël Desjardins⁶, Louis-Pierre Grenier⁷, Fares Kalache⁸, Christian Pineau⁹, Chantal Sauvageau¹⁰, Evelyne Vinet⁴ and Paul Fortin¹¹, ¹McGill University Health Centre, Montréal, QC, Canada, ²Centre de recherche du CHU de Québec – Université Laval, Quebec City, QC, Canada, ³Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁵The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁶Centre Hospitalier de l'Université de Montréal (CHUM)), Montreal, QC, Canada, ⁷Montreal General Hospital, Montréal, QC, Canada, ⁸McGill University Health Center, Montreal, QC, Canada, ⁹McGill University, Montréal, QC, Canada, ¹⁰Institut national de santé publique du Québec, Quebec City, QC, Canada, ¹¹Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada
Background/Purpose: Herpes Zoster (shingles) is a common preventable adverse event in SLE. In Quebec, Canada, the Recombinant Zoster Vaccine (RZV) became free of charge for…
Abstract Number: 2574 • ACR Convergence 2025
Differences in SARS-CoV-2 Antigen Persistence in Individuals with Systemic Autoimmune Rheumatic Diseases Compared to the General Population
Naomi Patel¹, Zoe Swank², Jiaqi Wang¹, Xiaosong Wang³, Lauren O'Keeffe², Madison Negron⁴, Liya Sisay Getachew⁵, Louise Hansen⁶, Grace Qian², Alene Saavedra², Kevin Mueller², Natalie Davis⁷, Kathleen Vanni⁵, Zachary Wallace⁸, David Walt² and Jeffrey Sparks⁵, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, Natick, MA, ⁴Harvard Extension School, Medford, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, B, ⁷Brigham and Women's Hospital, Brookline, MA, ⁸Massachusetts General Hospital, Newton, MA
Background/Purpose: Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post-acute COVID-19 outcomes due to use of immunosuppressive medications and…
Abstract Number: 1540 • ACR Convergence 2025
Association of Hypoalbuminemia with Serious Infections in Systemic Lupus Erythematosus Patients Receiving Dialysis
Ping Hsuan Kuo¹, Pu Jun Fang², Chien-Chih Lai³ and Yi-Syuan Sun⁴, ¹Taipei Veteran General Hospital, Taipei City, Taiwan (Republic of China), ²Tri-Service General Hospital, Hukou Township, Taiwan (Republic of China), ³Taipei Veterans General Hospital, Taipei City, Taiwan (Republic of China), ⁴taipei VGHTPE, ???, Taiwan (Republic of China)
Background/Purpose: Lupus nephritis, a key manifestation of systemic lupus erythematosus (SLE), can progress to end-stage kidney disease and increase patient burden. While patients with SLE…
Abstract Number: 0806 • ACR Convergence 2025
Comparative Risk of Infection-Related Complications in Systemic Lupus Erythematosus Patients Treated with Anifrolumab versus Belimumab: A Target Trial Emulation
Teng-Chieh Hsu¹, An-Ping Huo², Pei-Lun Liao², Pui-Ying Leong² and James Wei³, ¹Wuri Lin Shin Hospital, Taichung, Taiwan (Republic of China), ²Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), ³Chung Shan Medical University Hospital, Taichung, Taichung, Taiwan (Republic of China)
Background/Purpose: Anifrolumab and belimumab are biologic agents approved for systemic lupus erythematosus (SLE), yet their comparative safety profiles, particularly regarding infection risks, remain inadequately characterized…
Abstract Number: 0142 • ACR Convergence 2024
The Impact of Hospital Region on Mortality and Other Outcomes in Patients with Gout: A Two-Year Nationwide Analysis
Nidaa Rasheed¹, kHALED ABDULLAH² and Candice Reyes³, ¹UCSF Fresno, Fresno, CA, ²UCSF FRESNO, FRESNO, ³VACCHCS, Fresno, CA
Background/Purpose: Gout is characterized by chronic inflammatory arthritis caused by the deposition of monosodium urate crystals and leads to increased risk of complications, such as…
Abstract Number: 0261 • ACR Convergence 2024
Clinical Implications, Bacterial Profiles, and Patient Outcomes in Hospitalized Patients with Autoimmune Rheumatic Diseases
Angel Kevin Garza-Elizondo¹, Ana Cecilia Bardan-Inchaustegui², Pablo Gamez-Siller³, Diana Elsa Flores-Alvarado⁴, Jorge Esquivel-Valerio⁵, Jesus Cardenas-de la Garza², Elsa Catalina Davila-Correa⁶, Alejandra Jacquelin Osuna-Corrales⁶, Karla Judith Duran-Villarreal⁶, Daniela Alejandra Salcedo-Soto⁷, Derek de Jesus Gauna-Leal⁶, Andrea Axelle Prado-Prado⁶, Debanhi Morales-Espronceda⁶, Nathalia Valdez-Benavides⁶, Nirvana Amairany González-Ontiveros⁶ and Dionicio Galarza-Delgado⁸, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Facultad de Medicina UANL, Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico, ⁵Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, ⁶Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Mexico, ⁷Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico, ⁸UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Autoimmune rheumatic diseases (ARD) are chronic conditions that affect multiple organ systems. Patients with ARD tend to have a weak immune system due to…
Abstract Number: 1008 • ACR Convergence 2024
Immune Responses to Infection and Autoimmune Diseases in the UK Biobank
Choa Yun¹, May A. Beydoun², Lenore Launer² and Minkyo Song³, ¹National Institute on Aging, Rockville, MD, ²National Institute on Aging, Baltimore, MD, ³National Institutes on Aging, Baltimore, MD
Background/Purpose: Infections have been implicated as potential triggers for autoimmune responses, but studies primarily focused on the history of infection linked with autoimmune diseases. Large-scale…
Abstract Number: 2242 • ACR Convergence 2024
A Cross-sectional Study on Predictors of COVID-19 Infection, Admission and Mortality and Effect of Immunomodulating Treatments in Rheumatoid Arthritis
Mohammad Movahedi¹, Elliot Hepworth², Angela Cesta³, Xiuying Li³, Claire Bombardier⁴ and Sibel Aydin⁵, and OBRI investogators, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³UHN, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: COVID-19 infection frequently leads to a cytokine storm, which has successfully been treated with some immunomodulating therapies according to observational studies. Interestingly, treatments investigated…
Abstract Number: 0151 • ACR Convergence 2024
Immunoproteomic Profiling of Antibodies in Autoimmune Diseases
Choa Yun¹, Ji Qiu², M. Constanza Camargo³, Lusheng Song², Joshua LaBaer², Hyokyoung G. Hong³, Eric A. Engels³, Maddy Edie-Booker⁴, Adam Schiffenbauer⁵, Lisa Rider⁶, Frederick Miller⁷, Sarfaraz Hasni⁵, Blake M. Warner⁵, Mārcis Leja⁸ and Minkyo Song⁹, ¹National Institute on Aging, Rockville, MD, ²Arizona State University, Tempe, ³National Cancer Institute, Rockville, ⁴National Institute on Aging, Baltimore, MD, ⁵NATIONAL INSTITUTES OF HEALTH, Bethesda, MD, ⁶NIEHS, NIH, Garrett Park, MD, ⁷NIH, NIEHS, Chapel Hill, NC, ⁸University of Latvia, Rīga, Latvia, ⁹National Institutes on Aging, Baltimore, MD
Background/Purpose: Prior research has investigated a limited range of candidate markers within individual autoimmune diseases. This study aimed to identify specific and common autoantibodies and…
Abstract Number: 0262 • ACR Convergence 2024
Bartonella Endocarditis as an Important Mimic of ANCA Associated Vasculitis: Results of a Large Single Center Descriptive Analysis
Adam Brown¹, Adil Vural², Cassandra Calabrese³ and Leonard Calabrese², ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic Foundation, Cleveland Heights, OH
Background/Purpose: Infective Endocarditis (IE) is an important mimic of numerous forms of systemic vasculitis and especially Anti-Neutrophilic Cytoplasmic Antibody vasculitis (AAV). Bartonella endocarditis (BE) is…
Abstract Number: 1075 • ACR Convergence 2024
Optimizing Herpes Zoster Vaccination in Rheumatoid Arthritis Patients Ages 18-49 Years: A Quality Improvement Approach
Akhil Sood¹, Pegah Jahangiri¹, Christy Bill² and Janice Lin¹, ¹Stanford University, Palo Alto, CA, ²Stanford Health Care, Palo Alto, CA
Background/Purpose: Patients with rheumatoid arthritis are at increased risk for Herpes Zoster (HZ) infection, which is associated with increased hospitalizations and healthcare resource utilization. Despite…
Abstract Number: 2266 • ACR Convergence 2024
Immunosuppressive Medications and Common Infections in Patients with Rheumatoid Arthritis
Michael George¹, Kelly Gavigan², Shilpa Venkatachalam³, David Curtis², Laura Stradford⁴, William Benjamin Nowell⁵, Fenglong Xie⁶, Joshua Baker¹ and Jeffrey Curtis⁷, ¹University of Pennsylvania, Philadelphia, PA, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Regeneron, New York, NY, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Patients with RA are at increased risk of serious infection, but less is known about common, non-serious infections. Our prospective study aimed to assess…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].